Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 15/20 | 0.67 |
| ▸ | IKBKB | O14920 | 1/20 | 0.63 |
| ▸ | CHUK | O15111 | 1/20 | 0.63 |
| ▸ | JAK1 | P23458 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009483 | 0.88 | KIT (0.67) | KITIKBKBCHUKJAK1EGFR | |
| SCHEMBL30008731 | 0.88 | KIT (0.69) | KITIKBKBCHUKEGFRAURKB | |
| SCHEMBL30009814 | 0.83 | KIT (0.70) | KITIKBKBCHUKJAK2 | |
| SCHEMBL30009321 | 0.81 | IKBKB (0.66) | IKBKBCHUKJAK1 | |
| SCHEMBL24805256 | 0.81 | IKBKB (0.70) | KITIKBKBCHUKEGFRAURKB | |
| SCHEMBL15664194 | 0.81 | KIT (1.00) | KIT | |
| SCHEMBL30009296 | 0.80 | KIT (0.60) | KITIKBKBCHUKJAK1EGFR | |
| SCHEMBL30009248 | 0.78 | IKBKB (0.61) | KITIKBKBCHUKJAK1JAK2 | |
| SCHEMBL30009334 | 0.77 | IKBKB (0.60) | KITIKBKBCHUKJAK1EGFR | |
| SCHEMBL30009538 | 0.76 | KIT (0.69) | KITIKBKBCHUKJAK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | KIT 3668/4885IKBKB 294/4885CHUK 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.